4Li J, Zhu M, Manning-Bog AB, et al. Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson′s and Alzheimer′s disease. FASEB J, 2004,18:962-964. 被引量：1
5Foster HD, Hoffer A. The two faces of L-DOPA: benefits and adverse side effects in the treatment of Encephalitis lethargica, Parkinson′s disease, multiple sclerosis and amyotrophic lateral sclerosis. Med Hypotheses, 2004,62:177-181. 被引量：1
6Conway KA, Rochet JC, Bieganski RM, et al. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science, 2001, 294: 1346-1349. 被引量：1
7Lashuel HA, Petre BM, Wall J, et al. Alpha-synuclein, especially the Parkinson′s disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol, 2002, 322: 1089-1102. 被引量：1
8Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective a-Synuclein nitration in synucleinopathy lesions. Science, 2000, 290: 985-989. 被引量：1
9Yamin G, Uversky VN, Fink AL. Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. FEBS Lett, 2003,542:147-152. 被引量：1
10Koller WC. Levodopa in the treatment of Parkinson′s disease. Neurology, 2000,55(11 Suppl 4): S2-7. 被引量：1
